

GEPHE SUMMARY

CYP2C9 (https://www.gephebase.org/search-criteria?/and+GeneGephebase=~CYP2C9~#gephebase-summary-title)	Gephebase Gene	GP00000200	GepheID
	Entry Status	Martin	Main curator
	Published		

PHENOTYPIC CHANGE

Physiology (https://www.gephebase.org/search-criteria?/and+TraitCategory=~Physiology~#gephebase-summary-title)		Trait Category	
Xenobiotic resistance (anti-coagulant drug response) (https://www.gephebase.org/search-criteria?/and+Trait=~Xenobiotic resistance (anti-coagulant drug response)~#gephebase-summary-title)		Trait	
Homo sapiens - Caucasians and Japanese		Trait State in Taxon A	
Homo sapiens - Caucasians and Japanese		Trait State in Taxon B	
Data not curated		Ancestral State	
Intraspecific (https://www.gephebase.org/search-criteria?/and+TaxonomicStatus=~Intraspecific~#gephebase-summary-title)		Taxonomic Status	
Taxon A		Taxon B	
Homo sapiens (https://www.gephebase.org/search-criteria?/and+Taxon and Synonyms=~Homo sapiens~#gephebase-summary-title)		Homo sapiens (https://www.gephebase.org/search-criteria?/and+Taxon and Synonyms=~Homo sapiens~#gephebase-summary-title)	
human		human	
human; man; Homo sapiens Linnaeus, 1758; Home sapiens; Homo sampiens; Homo sapeins; Homo sapian; Homo sapians; Homo sapien; Homo sapience; Homo sapiense; Homo sapients; Homo sapines; Homo spaiens; Homo spiens; Humo sapiens		human; man; Homo sapiens Linnaeus, 1758; Home sapiens; Homo sampiens; Homo sapeins; Homo sapian; Homo sapians; Homo sapien; Homo sapience; Homo sapiense; Homo sapients; Homo sapines; Homo spaiens; Homo spiens; Humo sapiens	
species		species	
cellular organisms; Eukaryota; Opisthokonta; Metazoa; Eumetazoa; Bilateria; Deuterostomia; Chordata; Craniata; Vertebrata; Gnathostomata; Teleostomi; Euteleostomi; Sarcopterygii; Dipnotetrapodomorpha; Tetrapoda; Amniota; Mammalia; Theria; Eutheria; Boreoeutheria; Euarchontoglires; Primates; Haplorrhini; Simiiformes; Catarrhini; Hominoidea; Hominidae; Homininae; Homo		cellular organisms; Eukaryota; Opisthokonta; Metazoa; Eumetazoa; Bilateria; Deuterostomia; Chordata; Craniata; Vertebrata; Gnathostomata; Teleostomi; Euteleostomi; Sarcopterygii; Dipnotetrapodomorpha; Tetrapoda; Amniota; Mammalia; Theria; Eutheria; Boreoeutheria; Euarchontoglires; Primates; Haplorrhini; Simiiformes; Catarrhini; Hominoidea; Hominidae; Homininae; Homo	
Homo () - (Rank: genus) (https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=9605)		Homo () - (Rank: genus) (https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=9605)	
9606 (https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=9606)		9606 (https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id=9606)	
No		No	

GENOTYPIC CHANGE

CYP2C9	Generic Gene Name	UniProtKB Homo sapiens
CPC9; CYP2C; CYP2C10; CYP11C9; P45011C9	Synonyms	GenebankID or UniProtKB
9606.ENSPO00000260682 (http://string-db.org/newstring.cgi/show_network_section.pl?identifier=9606.ENSPO00000260682)	String	M21939 (https://www.ncbi.nlm.nih.gov/nuccore/M21939)
Belongs to the cytochrome P450 family.	Sequence Similarities	
GO:0016491 : oxidoreductase activity (https://www.ebi.ac.uk/QuickGO/term/GO:0016491)	GO - Molecular Function	
GO:0020037 : heme binding (https://www.ebi.ac.uk/QuickGO/term/GO:0020037)		
GO:0005506 : iron ion binding (https://www.ebi.ac.uk/QuickGO/term/GO:0005506)		

GO:0004497 : monooxygenase activity
(<https://www.ebi.ac.uk/QuickGO/term/GO:0004497>)
GO:0034875 : caffeine oxidase activity
(<https://www.ebi.ac.uk/QuickGO/term/GO:0034875>)
GO:0016712 : oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen (<https://www.ebi.ac.uk/QuickGO/term/GO:0016712>)
GO:0008392 : arachidonic acid epoxigenase activity
(<https://www.ebi.ac.uk/QuickGO/term/GO:0008392>)
GO:0008144 : drug binding (<https://www.ebi.ac.uk/QuickGO/term/GO:0008144>)
GO:0008395 : steroid hydroxylase activity
(<https://www.ebi.ac.uk/QuickGO/term/GO:0008395>)

GO - Biological Process

GO:0055114 : oxidation-reduction process
(<https://www.ebi.ac.uk/QuickGO/term/GO:0055114>)
GO:0042737 : drug catabolic process (<https://www.ebi.ac.uk/QuickGO/term/GO:0042737>)
GO:0017144 : drug metabolic process (<https://www.ebi.ac.uk/QuickGO/term/GO:0017144>)
GO:0019373 : epoxigenase P450 pathway
(<https://www.ebi.ac.uk/QuickGO/term/GO:0019373>)
GO:0042738 : exogenous drug catabolic process
(<https://www.ebi.ac.uk/QuickGO/term/GO:0042738>)
GO:0042759 : long-chain fatty acid biosynthetic process
(<https://www.ebi.ac.uk/QuickGO/term/GO:0042759>)
GO:0032787 : monocarboxylic acid metabolic process
(<https://www.ebi.ac.uk/QuickGO/term/GO:0032787>)
GO:0016098 : monoterpene metabolic process
(<https://www.ebi.ac.uk/QuickGO/term/GO:0016098>)
GO:0097267 : omega-hydroxylase P450 pathway
(<https://www.ebi.ac.uk/QuickGO/term/GO:0097267>)
GO:0070989 : oxidative demethylation
(<https://www.ebi.ac.uk/QuickGO/term/GO:0070989>)
GO:0006805 : xenobiotic metabolic process
(<https://www.ebi.ac.uk/QuickGO/term/GO:0006805>)
GO:0043603 : cellular amide metabolic process
(<https://www.ebi.ac.uk/QuickGO/term/GO:0043603>)
GO:0006082 : organic acid metabolic process
(<https://www.ebi.ac.uk/QuickGO/term/GO:0006082>)
GO:0008202 : steroid metabolic process
(<https://www.ebi.ac.uk/QuickGO/term/GO:0008202>)
GO:0019627 : urea metabolic process (<https://www.ebi.ac.uk/QuickGO/term/GO:0019627>)

GO - Cellular Component

GO:0005737 : cytoplasm (<https://www.ebi.ac.uk/QuickGO/term/GO:0005737>)
GO:0043231 : intracellular membrane-bounded organelle
(<https://www.ebi.ac.uk/QuickGO/term/GO:0043231>)
GO:0005789 : endoplasmic reticulum membrane
(<https://www.ebi.ac.uk/QuickGO/term/GO:0005789>)
GO:0031090 : organelle membrane (<https://www.ebi.ac.uk/QuickGO/term/GO:0031090>)

No (https://www.gephebase.org/search-criteria?/and+Presumptive Null=~No~#gephebase-summary-title)	Presumptive Null
Coding (https://www.gephebase.org/search-criteria?/and+Molecular Type=~Coding~#gephebase-summary-title)	Molecular Type
SNP (https://www.gephebase.org/search-criteria?/and+Aberration Type=~SNP~#gephebase-summary-title)	Aberration Type
Nonsynonymous	SNP Coding Change
I359L	Molecular Details of the Mutation
Association Mapping (https://www.gephebase.org/search-criteria?/and+Experimental Evidence=~Association Mapping~#gephebase-summary-title)	Experimental Evidence

	Taxon A	Taxon B	Position
Codon	-	-	-
Amino-acid	-	-	-

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose. (2009) (https://pubmed.ncbi.nlm.nih.gov/19300499)	Main Reference
Takeuchi F; McGinnis R; Bourgeois S; Barnes C; Eriksson N; Soranzo N; Whittaker P; Ranganath V; Kumanduri V; McLaren W; Holm L; Lindh J; Rane A; Wadelius M; Deloukas P	Authors
We report the first genome-wide association study (GWAS) whose sample size (1,053 Swedish subjects) is sufficiently powered to detect genome-wide significance ($p < 1.5 \times 10^{-7}$) for polymorphisms that modestly alter therapeutic warfarin dose. The anticoagulant drug warfarin is widely prescribed for reducing the risk of stroke, thrombosis, pulmonary embolism, and coronary malfunction. However, Caucasians vary widely (20-fold) in the dose needed for therapeutic anticoagulation, and hence prescribed doses may be too low (risking serious illness) or too high (risking severe bleeding). Prior work established that approximately 30% of the dose variance is explained by single nucleotide polymorphisms (SNPs) in the warfarin drug target VKORC1 and another approximately 12% by two non-synonymous SNPs (*2, *3) in the cytochrome P450 warfarin-metabolizing gene CYP2C9. We initially tested each of 325,997 GWAS SNPs for association with warfarin dose by univariate regression and found the strongest statistical signals ($p < 10^{-78}$) at SNPs clustering near VKORC1 and the second lowest p-values ($p < 10^{-31}$)	Abstract

emanating from CYP2C9. No other SNPs approached genome-wide significance. To enhance detection of weaker effects, we conducted multiple regression adjusting for known influences on warfarin dose (VKORC1, CYP2C9, age, gender) and identified a single SNP (rs2108622) with genome-wide significance ($p = 8.3 \times 10^{-10}$) that alters protein coding of the CYP4F2 gene. We confirmed this result in 588 additional Swedish patients ($p < 0.0029$) and, during our investigation, a second group provided independent confirmation from a scan of warfarin-metabolizing genes. We also thoroughly investigated copy number variations, haplotypes, and imputed SNPs, but found no additional highly significant warfarin associations. We present power analysis of our GWAS that is generalizable to other studies, and conclude we had 80% power to detect genome-wide significance for common causative variants or markers explaining at least 1.5% of dose variance. These GWAS results provide further impetus for conducting large-scale trials assessing patient benefit from genotype-based forecasting of warfarin dose.

Additional References

Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese. (2010) (<https://pubmed.ncbi.nlm.nih.gov/20833655>)

RELATED GEPHE

Related Genes

4 (alcohol dehydrogenase (ADH1B), CYP4F2, MDR1, Vkorc1) (<https://www.gephebase.org/search-criteria?/or+Taxon ID=~9606~/and+Trait=Xenobiotic resistance/and+groupHaplotypes=true#gephebase-summary-title>)

Related Haplotypes

No matches found.

EXTERNAL LINKS

COMMENTS